keyword
MENU ▼
Read by QxMD icon Read
search

antiemetics for chemotherapy

keyword
https://www.readbyqxmd.com/read/28801850/amisulpride-in-the-prevention-of-nausea-and-vomiting-induced-by-cisplatin-based-chemotherapy-a-dose-escalation-study
#1
Jørn Herrstedt, Yvonne Summers, Gedske Daugaard, Thomas B Christensen, Karin Holmskov, Paul D Taylor, Gabriel M Fox, Alexander Molassiotis
PURPOSE: The purpose of this study was to investigate the antiemetic effect of the dopamine D2- and dopamine D3-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy. METHODS: This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.5 and 20 mg) of amisulpride against acute nausea and vomiting in the period 0-24 h after initiation of cisplatin-based chemotherapy. The 20 mg dose was also investigated in combination with the 5-HT3-receptor antagonist, ondansetron...
August 11, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28780725/a-review-of-oral-cannabinoids-and-medical-marijuana-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-a-focus-on-pharmacokinetic-variability-and-pharmacodynamics
#2
REVIEW
Melissa E Badowski
PURPOSE: Oral cannabinoids (i.e., dronabinol, nabilone) containing the active component of marijuana, delta(Δ)9-tetrahydrocannabinol (THC), are available for the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who have failed to adequately respond to conventional antiemetic therapy. The aim of this article is to provide an overview of the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of oral cannabinoids for patients with CINV...
August 5, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28765126/cost-utility-and-budget-impact-analyses-of-the-use-of-nepa-for-chemotherapy-induced-nausea-and-vomiting-prophylaxis-in-italy
#3
Umberto Restelli, Gabriella Saibene, Patrizia Nardulli, Roberta Di Turi, Erminio Bonizzoni, Francesca Scolari, Tania Perrone, Davide Croce, Luigi Celio
OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC)...
August 1, 2017: BMJ Open
https://www.readbyqxmd.com/read/28764837/supportive-treatments-for-patients-with-cancer
#4
Karin Jordan, Petra Feyer, Ulrike Höller, Hartmut Link, Bernhard Wörmann, Franziska Jahn
BACKGROUND: For the treatment of patients with cancer to be successful and well-tolerated, the complications and side effects of the disease and its treatment must be treated and limited as far as possible. Summarized recommendations based on the constantly increasing evidence in the area of supportive care must be defined, standardized, and communicated. METHODS: We systematically reviewed the literature on the topics of anemia, neutropenia, nausea/vomiting, diarrhea, oral mucositis, skin toxicity, and peripheral neurotoxicity induced by cancer treatment, as well as osseous complications, extravasation, and side effects of radiotherapy...
July 10, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28759346/antiemetics-american-society-of-clinical-oncology-clinical-practice-guideline-update
#5
Paul J Hesketh, Mark G Kris, Ethan Basch, Kari Bohlke, Sally Y Barbour, Rebecca Anne Clark-Snow, Michael A Danso, Kristopher Dennis, L Lee Dupuis, Stacie B Dusetzina, Cathy Eng, Petra C Feyer, Karin Jordan, Kimberly Noonan, Dee Sparacio, Mark R Somerfield, Gary H Lyman
Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature for the period of November 2009 to June 2016. Results Forty-one publications were included in this systematic review. A phase III randomized controlled trial demonstrated that adding olanzapine to antiemetic prophylaxis reduces the likelihood of nausea among adult patients who are treated with high emetic risk antineoplastic agents. Randomized controlled trials also support an expanded role for neurokinin 1 receptor antagonists in patients who are treated with chemotherapy...
July 31, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28735677/genetic-risk-factors-associated-with-antiemetic-efficacy-of-palonosetron-aprepitant-and-dexamethasone-in-japanese-breast-cancer-patients-treated-with-anthracycline-based-chemotherapy
#6
Satoshi Yokoyama, Satoshi Tamaru, Shinya Tamaki, Daisuke Nakanishi, Akiya Mori, Tomokazu Yamakawa, Takaaki Ao, Yasuhiko Sakata, Toshiro Mizuno, Takuya Iwamoto, Kenichi Watanabe, Makoto Simomura, Keiki Kawakami, Naomi Konishi, Shinichi Kageyama, Shoichiro Ohtani, Tomomi Yamada, Susumu Ban, Kazuya Ooi
INTRODUCTION: Breast cancer patients often receive anthracycline-based chemotherapy, and chemotherapy-induced nausea and vomiting (CINV) remains one of the most uncomfortable and distressing adverse reactions. Poor control of CINV reduces the relative dose intensity of chemotherapy agents, which has been associated with poor clinical outcomes and shorter survival. The aim of the present study was to identify genetic risk factors associated with anthracycline-based CINV. PATIENTS AND METHODS: We evaluated CINV attributable to anthracycline-based chemotherapy in Japanese breast cancer patients treated with an antiemetic regimen that included palonosetron, aprepitant, and dexamethasone...
June 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28691209/efficacy-of-the-oral-neurokinin-1-receptor-antagonist-aprepitant-for-nausea-and-vomiting-induced-by-cisplatin-and-carboplatin-in-japanese-patients-with-gynecological-cancer
#7
Masae Ikeda, Masako Shida, Takeshi Hirasawa, Toshinari Muramatsu, Mikio Mikami
AIM: This study was conducted to evaluate the efficacy and the difference in effects of the oral neurokinin-1(NK-1) receptor antagonist aprepitant for chemotherapy-induced nausea/vomiting (CINV) in Japanese patients with gynecological cancer receiving highly emetogenic (cisplatin) and moderately emetogenic (carboplatin) chemotherapy. METHODS: Aprepitant was added during the second course of chemotherapy in Japanese patients with grade ≥ 2 (Common Terminology Criteria for Adverse Events, version 3...
July 10, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28686330/gstp1-c-313a-g-xpd-c-934g-a-xpf-c-2505t-c-and-casp9-c-1339a-g-polymorphisms-and-severity-of-vomiting-in-head-and-neck-cancer-patients-treated-with-cisplatin-chemoradiation
#8
Juliana Carron, Leisa Lopes-Aguiar, Ericka Francislaine Dias Costa, Guilherme Augusto Silva Nogueira, Tathiane Regine Penna Lima, Eder Carvalho Pincinato, Marilia Berlofa Visacri, Júlia Coelho França Quintanilha, Patrícia Moriel, Gustavo Jacob Lourenço, Carmen Silvia Passos Lima
Cisplatin (CDDP) chemotherapy associated with radiation (RT) has been used in advanced head and neck squamous cell carcinoma (HNSCC) patients, and vomiting is a common side effect during treatment. This prospective study aimed to identify the roles of GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G, XPC c.2815A>C, XPD c.934G>A and c.2251A>C, XPF c.2505T>C, ERCC1 c.354C>T, MLH1 c.-93G>A, MSH2 c.211 + 9C>G, MSH3 c.3133G>A, EXO1 c.1765G>A, TP53 c.215G>C, CASP3 c.-1191A>G and c...
July 7, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28671265/corticosteroids-for-adult-patients-with-advanced-cancer-who-have-nausea-and-vomiting-not-related-to-chemotherapy-radiotherapy-or-surgery
#9
REVIEW
Petra Vayne-Bossert, Alison Haywood, Phillip Good, Sohil Khan, Kirsty Rickett, Janet R Hardy
BACKGROUND: Nausea is a common symptom in advanced cancer, with a prevalence of up to 70%. While nausea and vomiting can be related to cancer treatments, such as chemotherapy, radiotherapy, or surgery, a significant number of people with advanced cancer also suffer from nausea unrelated to such therapies. Nausea and vomiting may also cause psychological distress, and have a negative impact on the quality of life of cancer patients; similarly to pain, nausea is often under-treated. The exact mechanism of action of corticosteroids on nausea is unclear, however, they are used to manage a number of cancer-specific complications, including spinal cord compression, raised intracranial pressure, and lymphangitis carcinomatosis...
July 3, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28658796/comparison-of-antiemetic-effectiveness-of-palonosetron-versus-ondansetron-in-patients-on-cancer-chemotherapy-a-prospective-observational-study-in-south-indians
#10
Abdul Aslam Parathoduvil, Asha Sisupalan, Padanayil Lekshmikutty Rema
INTRODUCTION: Chemotherapy Induced Nausea and Vomiting (CINV) is the most distressing side effect of cancer chemotherapy. It can seriously produce an impact on patient's quality of life. Prevention of CINV is far more effective than treatment of an established CINV. If the patient receives an optimal antiemetic regimen during the initial course of chemotherapy, the likelihood of developing emesis is greatly reduced. Although, all first generation 5HT3 antagonists demonstrate reasonable efficacy in preventing acute CINV, delayed CINV still remains a problem...
May 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28657216/additive-effect-of-rikkunshito-an-herbal-medicine-on-chemotherapy-induced-nausea-vomiting-and-anorexia-in-uterine-cervical-or-corpus-cancer-patients-treated-with-cisplatin-and-paclitaxel-results-of-a-randomized-phase-ii-study-jortc-kmp-02
#11
Shunsuke Ohnishi, Hidemichi Watari, Maki Kanno, Yoko Ohba, Satoshi Takeuchi, Tempei Miyaji, Shunsuke Oyamada, Eiji Nomura, Hidenori Kato, Toru Sugiyama, Masahiro Asaka, Noriaki Sakuragi, Takuhiro Yamaguchi, Yasuhito Uezono, Satoru Iwase
OBJECTIVE: Rikkunshito, an herbal medicine, is widely prescribed in Japan for the treatment of anorexia and functional dyspepsia, and has been reported to recover reductions in food intake caused by cisplatin. We investigated whether rikkunshito could improve chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients treated with cisplatin. METHODS: Patients with uterine cervical or corpus cancer who were to receive cisplatin (50 mg/m² day 1) and paclitaxel (135 mg/m² day 0) as first-line chemotherapy were randomly assigned to the rikkunshito group receiving oral administration on days 0-13 with standard antiemetics, or the control group receiving antiemetics only...
September 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28633504/a-phase-ii-study-of-palonosetron-aprepitant-dexamethasone-and-olanzapine-for-the-prevention-of-cisplatin-based-chemotherapy-induced-nausea-and-vomiting-in-patients-with-thoracic-malignancy
#12
Kazuhisa Nakashima, Haruyasu Murakami, Kouichi Yokoyama, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Fumie Nishiyama, Mami Kikugawa, Masayo Kaneko, Yumiko Iwamoto, Satomi Koizumi, Keita Mori, Takeshi Isobe, Toshiaki Takahashi
Background: The three-drug combination of a 5-hydroxytryptamine type 3 receptor antagonist, a neurokinin 1 receptor antagonist and dexamethasone is recommended for patients receiving highly emetogenic chemotherapy. However, standard antiemetic therapy is not completely effective in all patients. Methods: We conducted an open-label, single-center, single-arm Phase II study to evaluate the efficacy of olanzapine in combination with standard antiemetic therapy in preventing chemotherapy-induced nausea and vomiting in patients with thoracic malignancy receiving their first cycle of cisplatin-based chemotherapy...
June 17, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28602709/factors-associated-with-the-use-of-potentially-inappropriate-medications-by-older-adults-with-cancer
#13
Cristiane Moreira Reis, Andrezza Gouvêa Dos Santos, Paula de Jesus Souza, Adriano Max Moreira Reis
OBJECTIVES: To determine the frequency and the factors associated with the use of potentially inappropriate medications (PIMs) by older adults with cancer at an onco-haematology ambulatory clinic of a teaching hospital in Brazil. MATERIAL AND METHODS: Patients aged 60years or older (n=160) subjected to parenteral antineoplastic chemotherapy from May to December 2015 and treated with one or more medications in the ambulatory clinic were interviewed. Data on medications, comorbidities, oncological diagnosis, and functional status were recorded...
July 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28595433/managing-chemotherapy-induced-nausea-and-vomiting-in-head-and-neck-cancer-patients-receiving-cisplatin-chemotherapy-with-concurrent-radiation
#14
Jordan Stinson, Kelvin Chan, Justin Lee, Ronald Chow, Paul Cheon, Angie Giotis, Mark Pasetka, Bo Angela Wan, Edward Chow, Carlo DeAngelis
BACKGROUND: The purpose was to retrospectively examine the anti-emetic regimens prescribed for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) for head and neck cancer patients receiving moderate- or high-emetogenic chemotherapy (MEC/HEC) along with concurrent radiation treatment at an outpatient ambulatory care center to determine the efficacy of anti-emetics prescribed. METHODS: Consecutive patients with head and neck cancers who initiated cisplatin chemotherapy with concurrent radiation treatment between January 2013 and June 2015 were investigated...
March 21, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/28581463/the-burden-of-chemotherapy-induced-nausea-and-vomiting-in-children-receiving-hematopoietic-stem-cell-transplantation-conditioning-a-prospective-study
#15
J Flank, J Sparavalo, H Vol, L Hagen, R Stuhler, D Chong, S Courtney, J J Doyle, A Gassas, T Schechter, L L Dupuis
This prospective study describes chemotherapy-induced nausea and vomiting (CINV) in children (4-18 years) receiving their first hematopoietic stem cell transplant. Emetic episodes, nausea severity (assessed using a validated, self-report nausea severity assessment tool) and antiemetic administration were documented from the start of conditioning until 24 h after the last conditioning agent was administered (acute) and for a further 7 days (delayed). Relationships between CINV control and parenteral nutrition (PN) use and acute gut GvHD (aGvHD) were explored...
June 5, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28503222/olanzapine-for-chemotherapy-induced-nausea-and-vomiting-systematic-review-and-meta-analysis
#16
Legese Chelkeba, Kidu Gidey, Ayele Mamo, Berhane Yohannes, Tsehay Matso, Tsegaye Melaku
BACKGROUND: Chemotherapy induced nausea and vomiting (CINV) remains the most distressing event in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). OBJECTIVE: Therefore, this meta-analysis was conducted to evaluate the efficacy of olanzapine containing regimen in preventing acute, delayed and overall phases of CINV. METHODS: PubMed, EBSCO, and Cochrane central register of controlled trials electronic databases were searched to identify RCTs that compared the effects of olanzapine with non-olanzapine regimen in preventing CINV...
January 2017: Pharmacy Practice
https://www.readbyqxmd.com/read/28501134/factors-associated-with-palliative-care-use-in-patients-undergoing-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#17
Rachel S Morris, Faiz Gani, Abdulrahman Y Hammad, Wendy Peltier, T Clark Gamblin, Kiran K Turaga, Fabian M Johnston
BACKGROUND: Peritoneal carcinomatosis represents widespread metastatic disease throughout the abdomen and/or pelvis. Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) improves the overall survival compared to standard therapy alone. The role palliative care (PC) plays however, remains poorly studied among these patients. METHODS: Patients who had previously undergone HIPEC and who underwent an inpatient admission from 7/1/2013 to 6/30/2014 were identified to determine which patients were referred for inpatient or outpatient palliative consultation...
May 1, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28500750/nausea-and-vomiting-in-children-and-adolescents-receiving-intrathecal-methotrexate-a-prospective-observational-study
#18
Jacqueline Flank, Komail Nadeem, Sheliza Moledina, Mila Khanna, Christina Schindera, Angela Punnett, L Lee Dupuis
BACKGROUND: The prevalence of nausea and vomiting after receipt of intrathecal methotrexate (IT-MTX) in pediatric oncology patients is unknown. METHODS: Patients (4-18 years) about to receive IT-MTX were eligible to participate in this prospective, observational study. Patients received antiemetics as prescribed by their clinical team. Nausea severity (patient-assessed), timing of emetic episodes, and administration of antiemetics were recorded beginning immediately prior to IT-MTX administration, for the next 24 hr (acute phase), and for a maximum of 7 additional days (delayed phase)...
May 13, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28486012/adherence-to-and-implementation-of-asco-antiemetic-guidelines-in-routine-practice-in-a-tertiary-cancer-center-in-india
#19
Vijay M Patil, Vanita Noronha, Amit Joshi, Anant Ramaswamy, Sudeep Gupta, Arvind Sahu, Vipul Doshi, Tarachand Gupta, Sushmita Rath, Shripad Banavali, Kumar Prabhash
BACKGROUND: Nonadherence of antiemetic prescriptions to evidence-based antiemetic guidelines is associated with an increased proportion of chemotherapy-induced nausea and vomiting. The current project was carried out to improve the quality of antiemetic prescriptions at our institute. METHODS: We initially performed a retrospective analysis of 1,211 consecutive antiemetic prescription records of adult patients with solid tumors who received outpatient chemotherapy regimens...
June 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28470980/aprepitant-and-fosaprepitant-drug-interactions-a-systematic-review
#20
Priya Patel, J Steven Leeder, Micheline Piquette-Miller, L Lee Dupuis
AIMS: Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome P450 activity. This systematic review evaluates clinically significant pharmacokinetic drug interactions with aprepitant and fosaprepitant and describes adverse events ascribed to drug interactions with aprepitant or fosaprepitant. METHODS: We systematically reviewed the literature to September 11, 2016 to identify articles evaluating drug interactions involving aprepitant/fosaprepitant...
May 4, 2017: British Journal of Clinical Pharmacology
keyword
keyword
32975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"